As many as 20 patients with neurocirculatory dystonia (NCD) and 10 IHD patients presenting with stable exertional angina were evaluated for an effectiveness of antianginal action of validol tablets commercially- and noncommercially produced, the above tablets being of the changed composition in the latter case. Validol of both changed and unchanged composition had a similar transient antianginal effect which was higher in NCD than it was in angina pectoris. Economical as well as clinical effects of validol of the changed make up warrant it to be commercially produced.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
New insights on pharmacological and therapeutic potentials of trimetazidine beyond anti-anginal drug: A comprehensive review.
Eur J Pharmacol
December 2024
Department of Pharmacology, Therapeutics & Toxicology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Idi-Araba, P.M.B. 12003, Lagos, Nigeria. Electronic address:
Trimetazidine (TMZ) is a beneficial and well-tolerable anti-anginal drug which has protective action towards ischemia and reperfusion injury. TMZ performs its anti-ischemic effect by modifying cardiac metabolism without shifting the hemodynamic functions, so it represents an outstanding complementary perspective to the general angina treatment. TMZ possesses a positive impact on the inflammatory profile, and also endothelial function furthermore displays various benefits through minimising the number, as well as the intensity of angina strikes and ameliorating the clinical indication and symptoms of myocardium ischemia.
View Article and Find Full Text PDFRanolazine Unveiled: Rediscovering an Old Solution in a New Light.
J Clin Med
August 2024
Second Division of Cardiology, Cardio-Thoracic and Vascular Department, Pisa University Hospital, 56124 Pisa, Italy.
Ranolazine is an anti-anginal medication that has demonstrated antiarrhythmic properties by inhibiting both late sodium and potassium currents. Studies have shown promising results for ranolazine in treating both atrial fibrillation and ventricular arrhythmias, particularly when used in combination with other medications. This review explores ranolazine's mechanisms of action and its potential role in cardiac arrhythmias treatment in light of previous clinical studies.
View Article and Find Full Text PDFMeldonium Supplementation in Professional Athletes: Career Destroyer or Lifesaver?
Cureus
July 2024
Biochemistry, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Târgu Mureș, ROU.
Meldonium is a substance with known anti-anginal effects demonstrated by numerous studies and human clinical trials; however, it does not possess marketing authorization within the European Union, only in ex-Soviet republics. Since 2016, meldonium has been included by the World Anti-doping Agency (WADA) on the S4 list of metabolic modulators. In performance athletes, meldonium is now considered a doping agent due to its capacity to decrease lactate production during and after exercise, its capability to enhance the storage and utilization of glycogen, and its protective action against oxidative stress.
View Article and Find Full Text PDFTherapeutic potential of nicorandil beyond anti-anginal drug: A review on current and future perspectives.
Heliyon
April 2024
Department of Pharmacology, Therapeutics & Toxicology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Idi-Araba, P.M.B. 12003 Lagos, Nigeria.
Nicorandil (NIC) is a well-known anti-anginal agent, which has been recommended as one of the second-line treatments for chronic stable angina as justified by the European guidelines. It shows an efficacy equivalent to that of classic anti-anginal agents. NIC has also been used clinically in various cardiovascular diseases such as variant or unstable angina and reperfusion-induced damage following coronary angioplasty or thrombolysis.
View Article and Find Full Text PDFMechanism of action and neuroprotective role of nicorandil in ischemic stroke.
Heliyon
February 2024
Histomorphometry & Stereology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Nicorandil is a dual mechanism anti-anginal agent that acts as a nitric oxide (NO) donor and a potassium (K) channel opener. Recent studies have evaluated the effect of nicorandil on ischemic stroke. Neurons have a low tolerance to hypoxia and therefore the brain tissue is significantly vulnerable to ischemia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!